Future treatment of vascular calcification in chronic kidney diseaseMario Cozzolino, Giuseppe Cianciolo, Federico Maffei Faccioli et al.|Expert Opinion on Pharmacotherapy|2023Cited by 16
Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiencyAndrea Galassi, Mario Cozzolino, Giulia Porata et al.|Expert Opinion on Drug Safety|2021Cited by 10
Do SGLT2 inhibitors protect elderly patients from HF rehospitalization and CKD progression? More opportunities than concernsAndrea Galassi, Mario Cozzolino, Anila Cara et al.|International Journal of Cardiology|2022Cited by 2
#532 Association between blood flow measured within 30 days from AV access creation and the risk of thrombosisLorenza Magagnoli, Mario Cozzolino, Anila Cara et al.|Nephrology Dialysis Transplantation|2024Cited by 0
[Hypoxia-Inducible Factor Prolyl Hydroxylase Enzyme Inhibitors: A Novel Therapy for Anemia Treatment in CKD Patients].Andrea Stucchi, Mario Cozzolino, Lorenza Magagnoli et al.|PubMed|2024Cited by 0